NVLNF has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NVLNF has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Novelion Therapeutics's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2019 was $-16.0 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2019 was $-42.4 Mil.
EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Novelion Therapeutics's annualized ROC % for the quarter that ended in Mar. 2019 was -10.27%. Novelion Therapeutics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2019 was -4,577.81%.
EBIT is also linked to Joel Greenblatt's definition of earnings yield. Novelion Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2019 was -307.22%.
The historical data trend for Novelion Therapeutics's EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Novelion Therapeutics Annual Data | |||||||||||||||||||||
Trend | Dec09 | Dec10 | Dec11 | Dec12 | Dec13 | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | |||||||||||
EBIT | Get a 7-Day Free Trial | -31.49 | -26.01 | -36.71 | -84.26 | -47.92 |
Novelion Therapeutics Quarterly Data | ||||||||||||||||||||
Jun14 | Sep14 | Dec14 | Mar15 | Jun15 | Sep15 | Dec15 | Mar16 | Jun16 | Sep16 | Dec16 | Mar17 | Jun17 | Sep17 | Dec17 | Mar18 | Jun18 | Sep18 | Dec18 | Mar19 | |
EBIT | Get a 7-Day Free Trial | -21.48 | -17.89 | -9.58 | 1.03 | -15.99 |
For the Biotechnology subindustry, Novelion Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Novelion Therapeutics's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Novelion Therapeutics's EV-to-EBIT falls into.
EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.
EBIT for the trailing twelve months (TTM) ended in Mar. 2019 adds up the quarterly data reported by the company within the most recent 12 months, which was $-42.4 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Novelion Therapeutics (OTCPK:NVLNF) EBIT Explanation
1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.
Novelion Therapeutics's annualized ROC % for the quarter that ended in Mar. 2019 is calculated as:
ROC % (Q: Mar. 2019 ) | ||||||
= | NOPAT | / | Average Invested Capital | |||
= | Operating Income * ( 1 - Tax Rate % ) | / | ( (Invested Capital (Q: Dec. 2018 ) | + | Invested Capital (Q: Mar. 2019 )) | / count ) |
= | -63.952 * ( 1 - 0.66% ) | / | ( (601.519 | + | 635.322) | / 2 ) |
= | -63.5299168 | / | 618.4205 | |||
= | -10.27 % |
where
Invested Capital | (Q: Dec. 2018 ) | |||||||||||
= | Total Assets | - | Accounts Payable & Accrued Expense | - | Excess Cash | |||||||
= | Total Assets | - | Accounts Payable & Accrued Expense | - | ( Cash, Cash Equivalents, Marketable Securities | - | max(0, Total Current Liabilities | - | Total Current Assets | + | Cash, Cash Equivalents, Marketable Securities | )) |
= | 341.715 | - | 48.041 | - | ( 45.154 | - | max(0, 410.388 | - | 102.543 | + | 45.154 | )) |
= | 601.519 |
Invested Capital | (Q: Mar. 2019 ) | |||||||||||
= | Total Assets | - | Accounts Payable & Accrued Expense | - | Excess Cash | |||||||
= | Total Assets | - | Accounts Payable & Accrued Expense | - | ( Cash, Cash Equivalents, Marketable Securities | - | max(0, Total Current Liabilities | - | Total Current Assets | + | Cash, Cash Equivalents, Marketable Securities | )) |
= | 342.12 | - | 44.038 | - | ( 51.919 | - | max(0, 443.459 | - | 106.219 | + | 51.919 | )) |
= | 635.322 |
Note: The Operating Income data used here is four times the quarterly (Mar. 2019) data.
2. Joel Greenblatt's definition of Return on Capital:
Novelion Therapeutics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2019 is calculated as:
ROC (Joel Greenblatt) % | (Q: Mar. 2019 ) | ||||||
= | EBIT | / | Average of (Net fixed Assets | + | Net Working Capital) | ||
= | EBIT | / | Average of (Property, Plant and Equipment | + | Net Working Capital) | ||
Q: Dec. 2018 | Q: Mar. 2019 | ||||||
= | EBIT | / | ( ( (Property, Plant and Equipment + Net Working Capital) | + | (Property, Plant and Equipment + Net Working Capital) ) | / | count ) |
= | -63.952 | / | ( ( (1.585 + max(-4.507, 0)) | + | (1.209 + max(-29.706, 0)) ) | / | 2 ) |
= | -63.952 | / | ( ( 1.585 | + | 1.209 ) | / | 2 ) |
= | -63.952 | / | 1.397 | ||||
= | -4,577.81 % |
where Working Capital is:
Working Capital | (Q: Dec. 2018 ) | ||||||||||
= | (Accounts Receivable | + | Total Inventories | + | Other Current Assets) | - | (Accounts Payable & Accrued Expense | + | Defer. Rev. | + | Other Current Liabilities) |
= | (28.912 | + | 12.745 | + | 15.732) | - | (48.041 | + | 0 | + | 13.855) |
= | -4.507 |
Working Capital | (Q: Mar. 2019 ) | ||||||||||
= | (Accounts Receivable | + | Total Inventories | + | Other Current Assets) | - | (Accounts Payable & Accrued Expense | + | Defer. Rev. | + | Other Current Liabilities) |
= | (26.875 | + | 13.407 | + | 14.018) | - | (44.038 | + | 24.167 | + | 15.801) |
= | -29.706 |
When net working capital is negative, 0 is used.
Note: The EBIT data used here is four times the quarterly (Mar. 2019) EBIT data.
3. It is also linked to Joel Greenblatt's definition of Earnings Yield:
Novelion Therapeutics's Earnings Yield (Joel Greenblatt) % for today is calculated as:
Earnings Yield (Joel Greenblatt) % | = | EBIT (TTM) | / | Enterprise Value (Q: Mar. 2019 ) |
= | -42.427 | / | 13.810 | |
= | -307.22 % |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Novelion Therapeutics's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.
Kevin Kotler | 10 percent owner | C/O BROADFIN CAPITAL, LLC, 300 PARK AVENUE, 25TH FLOOR, NEW YORK NY 10022 |
Broadfin Capital, Llc | 10 percent owner | 300 PARK AVENUE, 25TH FLOOR, NEW YORK NY 10022 |
Broadfin Healthcare Master Fund Ltd | 10 percent owner | C/O 20 GENESIS CLOSE, ANSBACHER HOUSE, 2ND FLOOR, PO BOX 1344, GRAND CAYMAN E9 KY1-1108 |
Stonepine Capital, L.p. | 10 percent owner | 919 NW BOND STREET, SUITE 204, BEND OR 97703 |
Michael Dennis Price | officer: Chief Financial Officer | |
Benjamin Harshbarger | officer: See Remarks | ONE MAIN STREET, SUITE 800, CAMBRIDGE MA 02142 |
Mark Dipaolo | director | 660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830 |
John J Orloff | director | C/O BAXALTA INCORPORATED 1200 LAKESIDE DRIVE BANNOCKBURN IL 60015 |
Stephen L Sabba | director | DORSET MANAGEMENT CORP, 485 UNDERHILL BLVD SUITE 205, SYOSSET NY 11791 |
Mark Corrigan | director | |
Suzanne Louise Bruhn | director | C/O AEGLEA BIOTHERAPEUTICS, INC., 901 S. MOPAC EXPRESSWAY, SUITE 250, AUSTIN TX 78746 |
John C Thomas | director | 8601 SIX FORKS ROAD, SUITE 160, RALEIGH NC 27615 |
Murray Stewart | officer: Executive Vice President, R&D | C/O NOVELION THERAPEUTICS INC., 1800-510 WEST GEORGIA STREET, VANCOUVER A1 V6B OM3 |
Jason Aryeh | director | 11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037 |
Mary T Szela | director, officer: Chief Executive Officer | 10835 ROAD TO THE CURE, SUITE 205, SAN DIEGO CA 92121 |
From GuruFocus
By Marketwired Marketwired • 07-05-2019
By Marketwired Marketwired • 06-24-2019
By Marketwired Marketwired • 10-04-2019
By Marketwired Marketwired • 08-30-2019
By GlobeNewswire GlobeNewswire • 10-04-2019
By Marketwired Marketwired • 08-13-2019
By Marketwired Marketwired • 07-31-2018
By GlobeNewswire GlobeNewswire • 08-21-2019
By Marketwired Marketwired • 08-23-2018
By Marketwired Marketwired • 06-01-2018
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.